Last reviewed · How we verify

NCT04958278: ENDO-GREEN

Pelvic Sentinel Node Detection Using Indocyanine Green Learning Curve

Status unknown Last updated 12 July 2021
What this trial tests

trial in Endometrial Cancer in 30 participants. Status unknown.

Timeline
1 July 2021
Primary endpoint
31 October 2022
31 October 2022

Quick facts

Lead sponsorUniversity Hospital, Brest
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment30
Start date1 July 2021
Primary completion31 October 2022
Estimated completion31 October 2022
Sites1 location across France

Conditions studied

Sponsor

University Hospital, Brest

Who can join

18 and older, female only, with Endometrial Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

According to ESGO-ESTRO-ESMO guidelines, pelvic Sentinel lymph node detection is suitable for lymph node staging in endometrial carcinoma of the uteri. Nonetheless, a learning curve is mandatory to ensure the surgical quality of the sampling. The aim of the study is to assess the success of sentinel lymph node detection according to SHREC-Trial surgical strategy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Endometrial Cancer

Currently open trials in the same condition.

Other University Hospital, Brest trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04958278.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing